ORPHA:169805
Moderate hemophilia A
Also known as: Moderate congenital F8 deficiency · Moderate congenital factor VIII deficiency
Publications
926
85.2th percentile
Trials
3
Interventional, condition-specific
Researchers
1,216
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A moderately severe form of hemophilia A characterized by factor VIII deficiency (biological activity between 1 and 5 IU/dL) leading to abnormal bleeding as a result of minor injuries, or following trauma, surgery or tooth extraction. Spontaneous hemorrhages are rare. The condition primarily affects males but may also be observed in female carriers of disease-causing mutations.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015720
- UMLS:C0272323
Additional Mondo synonyms (3)
moderately severe factor VIII deficiency · moderately severe haemophilia type A · moderately severe hemophilia type A
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
926 matched papers (631 in last 10 years) Source
- Phenotype characterisedPresent
26 HPO annotations (e.g. Intraventricular hemorrhage; Epidural hemorrhage; Prolonged partial thromboplastin time) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
3 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
26
Associated phenotypes · MONDO:0015720
- Intraventricular hemorrhage
- Epidural hemorrhage
- Prolonged partial thromboplastin time
- Bleeding with minor or no trauma
- Intramuscular hematoma
Showing 5 of 26 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
926
926 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
926 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
631 in the last 10 years · high confidence · 85.2th percentile (publications denominator)
Phrase hits: 926 · MeSH hits: 0
Who's working on it?
1,216
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Castaman G8 papers · 2026
Department of Oncology, Center for Bleeding Disorders Careggi University Hospital Florence Italy.
Papers in Europe PMC - 02Coppens M8 papers · 2025
Department of Vascular Medicine Amsterdam University Medical Centers Amsterdam The Netherlands.
Papers in Europe PMC - 03Gouw SC8 papers · 2025
Amsterdam UMC University of Amsterdam, Emma Children's Hospital, Pediatric Hematology Amsterdam The Netherlands.
Papers in Europe PMC - 04Fijnvandraat K7 papers · 2025
Amsterdam UMC University of Amsterdam, Emma Children's Hospital, Pediatric Hematology Amsterdam The Netherlands.
Papers in Europe PMC - 05Leebeek FWG7 papers · 2025
Department of Hematology Erasmus MC, Erasmus University Medical Center Rotterdam The Netherlands.
Papers in Europe PMC - 06Fischer K6 papers · 2025
Van Creveldkliniek, Division of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Papers in Europe PMC - 07Oldenburg J6 papers · 2026
Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, 53127 Bonn, Germany.
Papers in Europe PMC - 08Olivieri M6 papers · 2026
Pediatric Thrombosis and Hemostasis Unit, Pediatric Hemophilia Center, Dr. von Hauner Children's Hospital, LMU München, Munich, Germany.
Papers in Europe PMC - 09Wang H5 papers · 2026
Department of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University , Chongqing ,
Papers in Europe PMC - 10Beckers EAM4 papers · 2023
Department of Internal Medicine, Division of Hematology, CARIM School for Cardiovascular Diseases Maastricht University Medical Center Maastricht The Netherlands.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
3
interventional trials for this specific condition
3 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 332 trials are registered for hemophilia A, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
3 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 86.7th percentile).
high confidence · 86.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
3 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05987449·RECRUITING·A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Not reviewed·Conditions: Hemophilia A·Matched via name phrase
Broader category: hemophilia A
332
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06816056·RECRUITING·Manual Therapy in Hemophilic Arthropathy of the Ankle
Not reviewed·Conditions: Hemophilia A·Matched via name phrase
- NCT06145373·RECRUITING·A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Not reviewed·Conditions: Hemophilia A·Matched via name phrase
- NCT05611801·RECRUITING·A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Not reviewed·Conditions: Hemophilia A · Hemophilia B·Matched via name phrase
- NCT05145127·RECRUITING·Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Not reviewed·Conditions: Hemophilia A · Hemophilia B·Matched via name phrase
- NCT07421154·NOT YET RECRUITING·Study of a Smart Sharps Disposal Device in Patients With Hemophilia
Not reviewed·Conditions: Hemophilia A and B·Matched via name phrase
- NCT07545395·RECRUITING·Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Not reviewed·Conditions: Hemophilia A or B·Matched via name phrase
- NCT07200609·NOT YET RECRUITING·The Effects of Virtual Reality-Based Gamified Rehabilitation in Children With Hemophilia
Not reviewed·Conditions: Hemophilia A Without Inhibitor·Matched via name phrase
- NCT03217032·RECRUITING·Lentiviral FVIII Gene Therapy
Not reviewed·Conditions: Hemophilia A·Matched via name phrase
- NCT07416526·RECRUITING·A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Not reviewed·Conditions: Hemophilia A·Matched via name phrase
- NCT07285460·RECRUITING·A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Not reviewed·Conditions: Hemophilia·Matched via name phrase
- NCT07226206·RECRUITING·A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Not reviewed·Conditions: Hemophilia A·Matched via name phrase
- NCT06864975·RECRUITING·Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
Not reviewed·Conditions: Hemophilia a with Inhibitor·Matched via name phrase
- NCT04728841·RECRUITING·Gene Therapy for Chinese Hemophilia A
Not reviewed·Conditions: Hemophilia A · Gene Therapy·Matched via name phrase
- NCT06320626·RECRUITING·Pharmacokinetic-guided Dosing of Emicizumab
Not reviewed·Conditions: Hemophilia A With Inhibitor · Hemophilia A Without Inhibitor · Hemophilia A, Severe · Adolescent·Matched via name phrase
- NCT06938659·NOT YET RECRUITING·Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients
Not reviewed·Conditions: Hemophilia A·Matched via name phrase
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 7 · after dedupe 7 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 7 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (7)
- ctis·2023-506610-52-00·Cancelled·A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients with Mild or Moderate Hemophilia A without FVIII Inhibitors
skipped — LLM skipped (--skip-llm)
- ctis·2023-505747-40-00·Expired·A Multicenter, Open-Label Phase IV Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes, in Participants Aged ≥13 and < 70 Years with Severe or Moderate Hemophilia a Without FVIII Inhibitors on Emicizumab Prophylaxis
skipped — LLM skipped (--skip-llm)
- ctis·2023-503906-35-00·Authorised, ongoing·A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons with Severe or Moderate Hemophilia A
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15852459·No longer recruiting·Diode laser-assisted tooth extraction versus conventional extraction in patients receiving antiplatelet therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10901752·No longer recruiting·Impact of astaxanthin on health and performance among firefighters
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10101701·No longer recruiting·A study to evaluate overall health, physical activity and joint outcomes, in participants with severe or moderate hemophilia A without FVIII inhibitors on emicizumab prophylaxis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN29749408·No longer recruiting·'SPOT Sign' seLection of Intracerebral haemorrhage to Guide Haemostatic therapy
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Moderate hemophilia A — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Moderate hemophilia A" OR "Moderate congenital F8 deficiency" OR "Moderate congenital factor VIII deficiency" OR "moderately severe factor VIII deficiency" OR "moderately severe haemophilia type A" OR "moderately severe hemophilia type A"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Moderate hemophilia A" OR "Moderate congenital F8 deficiency" OR "Moderate congenital factor VIII deficiency" OR "moderately severe factor VIII deficiency" OR "moderately severe haemophilia type A" OR "moderately severe hemophilia type A"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 3 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemophilia A"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T08:38:24.884Z
